MyoKardia Drug Moves to Next Phase

According to this press release, MyoKardia expects to dose the first patient in the EXPLORER-HCM trial of mavacamten (formerly known as MYK-461) for obstructive HCM in the second quarter of 2018.

MyoKardia says that it expects 220 patients to enroll in the 30 week long trial.  These patients will be randomly assigned to receive either mavacamten or a placebo.  Participants will also be able to continue on their normal beta blockers or calcium channel blockers.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s